Success Metrics

Clinical Success Rate

57.1%

Based on 4 completed trials

Completion Rate

57%(4/7)

Active Trials

1(11%)

Results Posted

50%(2 trials)

Terminated

3(33%)

Phase Distribution

Ph phase_1

44%

Ph not_applicable

11%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

4(50.0%)

Phase 2Efficacy & side effects

3(37.5%)

N/ANon-phased studies

1(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(4)

Terminated(3)

Other(1)

Detailed Status

Completed4

Terminated3

Active, not recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

57.1%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (50.0%)

Phase 23 (37.5%)

N/A1 (12.5%)

Trials by Status

terminated333%

active_not_recruiting111%

completed444%

unknown111%

Recent Activity

1 active trials

Showing 5 of 9

completednot_applicable

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

NCT04471844

active_not_recruitingphase_2

Niraparib/TTFields in GBM

NCT04221503

completedphase_1

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

NCT04474353

terminatedphase_2

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

NCT02663271

terminatedphase_2

Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

NCT03903640

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT04471844Not Applicable

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

Completed

NCT04221503Phase 2

Niraparib/TTFields in GBM

Active Not Recruiting

NCT04474353Phase 1

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

Completed

NCT02663271Phase 2

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

Terminated

NCT03903640Phase 2

Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

Terminated

NCT02903069Phase 1

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

Completed

NCT02893137Phase 1

Enhancing Optune Therapy With Targeted Craniectomy

Completed

NCT03403803

Prognosis and Therapeutic Biomarkers for Glioblastoma Patients

Terminated

NCT03687034Phase 1

A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma

Unknown

All 9 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 9